Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition
– – Accepted abstracts include Phase 2 safety, efficacy, and tolerability data for CAEL-101 in AL amyloidosis – – Phase 3 studies of CAEL-101 in AL amyloidosis are underway – BORDENTOWN, N.J. & BOSTON – November 04, 2020 11:55 AM Eastern Standard Time – (BUSINESS WIRE)–Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a first-in-class amyloid fibril targeted therapy, have been accepted for presentation at the